A deep joint-learning proteomics model for diagnosis of six conditions associated with dementia
Summary
Co-pathology is a common feature of neurodegenerative diseases that complicates diagnosis, treatment and clinical management. However, sensitive, specific and scalable biomarkers for in vivo pathological diagnosis are not available for most neurodegenerative neuropathologies. Here we present Proteomics-based Artificial Intelligence for Dementia Diagnosis (ProtAIDe-Dx), a deep joint-learning model on 17,187 patients and controls (age of 70.3 ± 11.5 years, 53.2% female), that uses plasma pro
Content
# A deep joint-learning proteomics model for diagnosis of six conditions associated with dementia
*Published: 2026 May*
Co-pathology is a common feature of neurodegenerative diseases that complicates
diagnosis, treatment and clinical management. However, sensitive, specific and
scalable biomarkers for in vivo pathological diagnosis are not available for
most neurodegenerative neuropathologies. Here we present Proteomics-based
Artificial Intelligence for Dementia Diagnosis (ProtAIDe-Dx), a deep
joint-learning model on 17,187 patients and controls (age of 70.3 ± 11.5 years,
53.2% female), that uses plasma proteomics to provide simultaneous probabilistic
diagnosis across 6 conditions associated with dementia in aging. ProtAIDe-Dx
achieves cross-validated balanced classification accuracy of 70-95% and area
under the curve of >78% across all conditions. The model's diagnostic
probabilities highlighted subgroups of patients with co-pathologies and were
associated with pathology-specific biomarkers in an external memory clinic
sample, even among individuals without cognitive impairment. Model
interpretation revealed a suite of protein networks marking shared and specific
biological processes across diseases and identified novel and previously
described proteins discriminating each diagnosis. ProtAIDe-Dx significantly
improved biomarker-based differential diagnosis in a memory clinic sample,
pinpointing proteins leading to diagnostic decisions at an individual level.
Together, this work highlights the promise of plasma proteomics to improve
patient-level diagnostic workup with a single blood draw.
DOI: 10.1038/s41591-026-04303-y